Cytosorbents Corporation (CTSO) Receives Consensus Rating of “Buy” from Analysts
Shares of Cytosorbents Corporation (NASDAQ:CTSO) have been assigned an average recommendation of “Buy” from the six analysts that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $10.45.
A number of equities analysts have recently weighed in on the company. ValuEngine lowered Cytosorbents Corporation from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. HC Wainwright reaffirmed a “buy” rating and set a $13.00 target price on shares of Cytosorbents Corporation in a research report on Tuesday, September 26th. Maxim Group set a $10.00 target price on Cytosorbents Corporation and gave the stock a “buy” rating in a research report on Monday, July 17th. Aegis reaffirmed a “buy” rating and set a $9.00 target price on shares of Cytosorbents Corporation in a research report on Tuesday, July 25th. Finally, B. Riley reaffirmed a “buy” rating and set a $11.25 target price on shares of Cytosorbents Corporation in a research report on Wednesday, August 2nd.
Shares of Cytosorbents Corporation (NASDAQ:CTSO) opened at 6.35 on Thursday. The firm’s market capitalization is $178.64 million. The firm’s 50-day moving average is $5.67 and its 200 day moving average is $4.85. Cytosorbents Corporation has a one year low of $3.30 and a one year high of $6.70.
Cytosorbents Corporation (NASDAQ:CTSO) last issued its quarterly earnings results on Monday, August 7th. The medical research company reported ($0.04) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.02. Cytosorbents Corporation had a negative return on equity of 529.95% and a negative net margin of 80.56%. The firm had revenue of $3.57 million for the quarter, compared to analyst estimates of $3.29 million. Equities research analysts predict that Cytosorbents Corporation will post ($0.27) earnings per share for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. raised its position in Cytosorbents Corporation by 145.2% in the 2nd quarter. PNC Financial Services Group Inc. now owns 38,000 shares of the medical research company’s stock valued at $163,000 after buying an additional 22,500 shares during the last quarter. Sabby Management LLC purchased a new stake in Cytosorbents Corporation in the 1st quarter valued at $990,000. Finally, Skylands Capital LLC raised its position in Cytosorbents Corporation by 87.7% in the 2nd quarter. Skylands Capital LLC now owns 594,250 shares of the medical research company’s stock valued at $2,555,000 after buying an additional 277,650 shares during the last quarter. 6.89% of the stock is owned by institutional investors and hedge funds.
About Cytosorbents Corporation
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corporation and related companies with MarketBeat.com's FREE daily email newsletter.